Leo Pharma meets big 2023 goal but substantial deficit remains
High interest rates on its billion-dollar debt are still impacting the 115-year-old pharmaceutical company’s bottom line.
Turning Leo Pharma into a profitable company that can make money from operations was the Leo Pharma management’s overriding goal for 2023.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
